A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...

Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan ...